Difference between revisions of "Telotristat (Xermelo)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[[Neuroendocrine tumors" to "[[Neuroendocrine tumor")
Line 13: Line 13:
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
*2/28/2017: [https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm544035.htm Initial FDA approval] to be used "in combination with [[:Category:Somatostatin analogs|somatostatin analog (SSA) therapy]] for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone has inadequately controlled."
+
*2/28/2017: [https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm544035.htm Initial FDA approval] to be used in combination with [[:Category:Somatostatin analogs|somatostatin analog (SSA) therapy]] for the treatment of adults with [[Neuroendocrine tumor|carcinoid]] syndrome diarrhea that SSA therapy alone has inadequately controlled.
  
 
==Also known as==
 
==Also known as==

Revision as of 12:51, 8 May 2021

General information

Class/mechanism: Tryptophan hydroxylase inhibitor. Tryptophan hydroxylase controls the rate limiting step of the biosynthesis of serotonin, which plays a role in regulating the secretion, motility, inflammation, and sensation of the gastrointestinal tract, and is over-produced in patients with carcinoid syndrome. Telotristat reduces the frequency of carcinoid syndrome diarrhea by decreasing the production of serotonin.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Generic name: telotristat ethyl as telotristat etiprate
  • Brand name: Xermelo

References